What is Eucalyptus?
Eucalyptus operates within Australia's healthcare system, a predominantly two-payer model where government funding covers most care, supplemented by private insurance. The company positions itself as a private-pay option, directly serving consumers. Founded in 2019 and headquartered in New South Wales, Eucalyptus aims to provide accessible healthcare solutions outside the traditional public and insurance-based frameworks. Its business model focuses on direct-to-consumer offerings, navigating the existing healthcare landscape by providing a distinct private payment pathway.
How much funding has Eucalyptus raised?
Eucalyptus has raised a total of $112.3M across 3 funding rounds:
Series A
$30M
Series B
$22.3M
Series C
$60M
Series A (2021): $30M with participation from Blackbird
Series B (2021): $22.3M led by Blackbird Ventures, W23, NewView Capital, and AirTree Ventures
Series C (2022): $60M supported by BOND
Key Investors in Eucalyptus
Blackbird
Blackbird is an Australian venture capital firm that exists to supercharge the company's most ambitious founders. Blackbird partners with founders at the very beginning and surrounds them with other founders who have built successful technology companies before.
Blackbird Ventures
Blackbird is an Australian venture capital firm that exists to supercharge the company's most ambitious founders. Blackbird partners with founders at the very beginning and surrounds them with other founders who have built successful technology companies before.
NewView Capital
NewView Capital is a venture growth firm that specializes in investing in high-potential enterprise software and fintech companies through primary and secondary investments. The firm provides flexible capital tailored to the needs of its partners, along with operational guidance to help companies navigate critical growth decisions.
What's next for Eucalyptus?
The recent major strategic investment signifies a pivotal moment for Eucalyptus, likely enabling the company to accelerate its expansion and further penetrate the Australian healthcare market. This capital infusion is expected to fuel product development, enhance service offerings, and potentially broaden its consumer base. The company's focus on a direct-to-consumer private-pay model suggests a strategy aimed at capturing market share by offering convenience and tailored healthcare solutions. Future growth may involve scaling operations, refining its digital health platform, and potentially exploring new service verticals within the private healthcare segment.
See full Eucalyptus company page
